Skip to main content

Table 4 Longitudinal data for patients with GHD or ISS with growth disorders and 2-year data

From: Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program

Mean ± SD

GHD

ISS

HSDS

Baseline

n = 27

− 2.21 ± 0.93

n = 9

−2.44 ± 0.27

Start of AIT

n = 25

−1.00 ± 0.96

n = 9

− 0.85 ± 0.85

2 years after AIT

n = 27

− 0.40 ± 1.16

n = 9

−0.65 ± 0.52

BA/CA ratio

Baseline

n = 16

0.90 ± 0.11

n = 5

0.79 ± 0.20

Start of AIT

n = 23

0.98 ± 0.12

n = 9

1.02 ± 0.11

2 years after AIT

n = 10

0.95 ± 0.10

n = 8

0.96 ± 0.06

  1. AIT Aromatase inhibitor therapy, BA Bone age, CA Chronologic age, GHD Growth hormone deficiency, HSDS height standard deviation score; ISS, idiopathic short stature
Back to article page

International Journal of Pediatric Endocrinology

ISSN: 1687-9856

Contact us